Welcome to our dedicated page for Century Therapeutics news (Ticker: IPSC), a resource for investors and traders seeking the latest updates and insights on Century Therapeutics stock.
Century Therapeutics, Inc. develops induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer. Its platform uses an iPSC cell foundry and Allo-Evasion™ immune-evasion engineering to create allogeneic beta islet, T cell and natural killer cell programs, including CNTY-813 for type 1 diabetes and CD19-targeted CAR-iT work such as CNTY-308.
Recurring company updates address preclinical data presentations, regulatory-pathway disclosures, financial results, investor presentations, board and committee changes, and collaboration economics tied to the company’s collaboration, option and license agreement with Bristol-Myers Squibb.
Century Therapeutics (NASDAQ: IPSC) reported its Q1 2022 financial results, highlighting a cash position of $466.4 million and a net cash provided by operations of $86.8 million. The company plans to initiate its Phase 1 ELiPSE-1 trial for CNTY-101 in relapsed/refractory lymphoma in H2 2022 after IND submission. R&D expenses increased to $21.2 million, driven by expanded headcount and studies. The net loss stood at $37.5 million. The company expects its financial resources to sustain operations through 2025.
Century Therapeutics (NASDAQ: IPSC) announced participation in key investor conferences in May 2022. The management team will engage in a fireside chat at the Bank of America Securities 2022 Healthcare Conference on May 10 at 8:40 AM PT, and present at the H.C. Wainwright Global Investment Conference on May 24, available on-demand from 7:00 AM ET. Replays of these events will be accessible for 30 days on the Company’s website. Century focuses on iPSC-derived cell therapies for cancer treatment.
Century Therapeutics (NASDAQ: IPSC) announced that preclinical data on MAD7, a novel CRISPR nuclease enabling genetic engineering of iPSC-derived NK and T cell therapies, will be presented at the ASGCT 25th Annual Meeting from May 16-19, 2022, in Washington, D.C. The presentation will focus on enhancing iPSC-based cell therapies, with details including an abstract number of 952, scheduled for May 18, 2022, at 5:30 PM ET. The company aims to overcome limitations of first-generation cell therapies with its innovative approaches to cancer treatment.
On April 18, 2022, Century Therapeutics (NASDAQ: IPSC) announced that its management team will present at the virtual Chardan Genetic Medicines and Cell Therapy Manufacturing Summit on April 25, 2022, at 9:30 AM ET. A live webcast will be available on the company's website, and a replay will be archived for 30 days. The company specializes in developing iPSC-derived cell therapies to target hematologic and solid tumors, aiming to enhance patient access to cancer treatments.
Century Therapeutics (NASDAQ: IPSC) will have CEO Lalo Flores present at the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 10:15 AM ET. He will also participate in a panel discussing key features in NK Cellular Therapeutics on April 14, 2022, at 11:00 AM ET. A live webcast of the presentation will be available on the company’s website, with an archived replay for 30 days post-event. Century Therapeutics focuses on developing innovative iPSC-derived cell therapies aimed at treating hematologic and solid tumor cancers.
Century Therapeutics (NASDAQ: IPSC) announced that CEO Lalo Flores, Ph.D., will present at the H.C. Wainwright Gene Therapy and Gene Editing Conference on March 30, 2022. The presentation will focus on the company's development of induced pluripotent stem cell (iPSC)-derived cell therapies aimed at treating cancer. A recording will be available on their website starting March 30 at 7:00 AM ET for 90 days. Century's innovative approach seeks to advance cancer care by leveraging adult stem cells and genetic engineering.
Century Therapeutics (NASDAQ: IPSC) reported Q4 and full-year 2021 results, ending with $358.8 million in cash, ensuring operations into 2025. A strategic collaboration with Bristol Myers Squibb includes a $100 million upfront payment and a $50 million equity investment. The company plans to submit an IND for CNTY-101 in mid-2022 and initiate the Phase 1 ELiPSE-1 trial for relapsed/refractory lymphoma. R&D expenses rose to $75.6 million, contributing to a net loss of $95.8 million for 2021. The company anticipates operating expenses between $155 million and $165 million for 2022.
Century Therapeutics (NASDAQ: IPSC) announced that its senior management team will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 1:40 PM ET. A live webcast of the event will be accessible on Century's website and available for replay for 90 days. The company focuses on developing induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, aiming to address the limitations of traditional cell therapies and enhance patient access.
Bristol Myers Squibb (NYSE:BMY) has reported fourth quarter revenues of $12.0 billion, marking an 8% increase year-over-year, and full-year revenues of $46.4 billion. The fourth quarter earnings per share (EPS) stand at $1.07 (GAAP) and $1.83 (non-GAAP), with full-year EPS at $3.12 and $7.51 respectively, reflecting a 17% growth in non-GAAP EPS. The company has authorized a $15 billion share repurchase initiative and announced a $5 billion accelerated share repurchase agreement for Q1 2022. Guidance for 2022 includes projected revenues of approximately $47 billion.
Bristol Myers Squibb (NYSE:BMY) reported Q4 revenues of $12.0 billion, an 8% increase driven by robust sales of Eliquis and immuno-oncology products. Full-year revenues reached $46.4 billion, up 9%. Q4 earnings per share (EPS) stood at $1.07 (GAAP) and $1.83 (non-GAAP), with annual EPS at $3.12 and $7.51 respectively. The company announced a $15 billion share repurchase authorization and provided 2022 guidance, predicting $47 billion in revenues. The outlook includes expected growth from new products and a reduction in operating expenses.